Cytokeratin markers come of age

Tumor Biology

Volumn 28, Issue 4, 2007, Pages 189-195

  Linder, Stig ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Cytokeratin; M30 Apoptosense

Indexed keywords

BIOLOGICAL MARKER; CASPASE; CYTOKERATIN; CYTOKERATIN 18; MONOCLONAL ANTIBODY; TUMOR MARKER;

AGE; APOPTOSIS; CANCER PATIENT; CELL DEATH; CELL PROLIFERATION; DISEASE COURSE; HUMAN; IMMUNOASSAY; NECROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; REVIEW; TREATMENT RESPONSE; TUMOR CELL;

EID: 34548494871     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107582     Document Type: Review

References (77)

1. Steinert PM, Idler WW, Zimmerman SB: Self-assembly of bovine epidermal keratin filaments in vitro. J Mol Biol 1976;108:547-567.
2. Hatzfeld M, Franke WW: Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified poly - peptides. J Cell Biol 1985;101:1826-1841.
3. Vijayaraj P, Sohl G, Magin TM: Keratin transgenic and knockout mice: functional analysis and validation of disease-causing mutations. Methods Mol Biol 2007;360:203-251.
4. Moll R: Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 1994;9:63-69.
5. Schaafsma HE, Ramaekers FC, van Muijen GN, Lane EB, Leigh IM, Robben H, Huijsmans A, Ooms EC, Ruiter DJ: Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. Am J Pathol 1990;136:329-343.
6. Trask DK, Band V, Zajchowski DA, Yaswen P, Suh T, Sager R: Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci USA 1990;87:2319-2323.
7. Schussler MH, Skoudy A, Ramaekers F, Real FX: Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol 1992;140:559-568.
8. Oshima RG, Baribault H, Caulin C: Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev 1996;15:445-471.
9. Pankov R, Umezawa A, Maki R, Der CJ, Hauser CA, Oshima RG: Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway. Proc Natl Acad Sci USA 1994;91:873-877.
10. Schutte B, Henfling M, Kolgen W, Bouman M, Meex S, Leers MP, Nap M, Bjorklund V, Bjorklund P, Bjorklund B, Lane EB, Omary MB, Jornvall H, Ramaekers FC: Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004;297:11-26.
11. Ku NO, Liao J, Omary MB: Apoptosis generates stable fragments of human type I keratins. J Biol Chem 1997;272:33197-33203.
12. Ku NO, Omary MB: Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation. J Biol Chem 2001;276:26792- 26798.
13. Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FC, Björklund B, Nap M, Jörnvall H, Schutte B: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999;187:567-572.
14. Lee JC, Schickling O, Stegh AH, Oshima RG, Dinsdale D, Cohen GM, Peter ME: DEDD regulates degradation of intermediate filaments during apoptosis. J Cell Biol 2002;158:1051-1066.
15. Dinsdale D, Lee JC, Dewson G, Cohen GM, Peter ME: Intermediate filaments control the intracellular distribution of caspases during apoptosis. Am J Pathol 2004;164:395-407.
16. Kulesh DA, Cecena G, Darmon YM, Vasseur M, Oshima RG: Posttranslational regulation of keratins: degradation of mouse and human keratins 18 and 8. Mol Cell Biol 1989;9:1553-1565.
17. Björklund B, Björklund V: Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy Appl Immunol 1957;10:153-184.
18. Kirsch J, Oehr P, Winkler C: Localization of tissue polypeptide antigen in interphase HeLa cells by immunofluorescence microscopy. Tumordiagn Ther 1983;4:222-224.
19. Weber K, Osborn M, Moll R, Wiklund B, Luning B: Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J 1984;3:2707-2714.
20. Mellerick DM, Osborn M, Weber K: On the nature of serological tissue polypeptide antigen (TPA);monoclonal keratin 8, 18, and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum. Oncogene 1990;5:1007-1017.
21. Rydlander L, Ziegler E, Bergman T, Schoberl E, Steiner G, Bergman AC, Zetterberg A, Marberger M, Bjorklund P, Skern T, Einarsson R, Jornvall H: Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996;241:309-314.
22. Sundström BE, Stigbrand TI: Cytokeratins and tissue polypeptide antigen. Int J Biol Markers 1994;9:102-108.
23. Schneider J: Tumor markers in detection of lung cancer. Adv Clin Chem 2006;42:1-41.
24. Seregni E, Coli A, Mazzucca N: Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 2004;31(suppl 1):S15-S22.
25. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W, Fateh-Moghadam A: CYFRA 21-1: a new marker in lung cancer. Cancer 1993;72:707-713.
26. Nisman B, Barak V, Heching N, Kramer M, Reinus C, Lafair J: Cytokeratin markers in malignant pleural mesothelioma. Cancer Detect Prev 1998;22:416-421.
27. Rebhandl W, Rami B, Turnbull J, Felberbauer FX, Paya K, Bancher-Todesca D, Gherardini R, Mittlboeck M, Horcher E: Diagnostic value of tissue polypeptide-specific antigen (TPS) in neuroblastoma and Wilms' tumour. Br J Cancer 1998;78:1503-1506.
28. Tempfer C, Hefler L, Haeusler G, Reinthaller A, Koelbl H, Zeisler H, Kainz C: Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients. Int J Cancer 1998;79:241-244.
29. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D: Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 1999;85:1018-1025.
30. Doweck I, Barak M, Uri N, Greenberg E: The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 2000;83:1696-1701.
31. Barak V, Goike H, Panaretakis KW, Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37:529-540.
32. Ho YJ, Hsieh JF, Tasi SC, Lee JK, Kao CH: Tissue polypeptide specific antigen and squamous cell carcinoma antigen for early prediction of recurrence in lung squamous cell carcinoma. Lung 2000;178:75-80.
33. Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T, Barak V: Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999;19:3549-3552.
34. Sutterlin M, Oehler MK, Caffier H: Clinical value of CYFRA 8/18 and TPS in the diagnosis and follow up of invasive breast cancer. Anticancer Res 1997;17:2963-2965.
35. Sjöström J, Alfthan H, Joensuu H, Stenman UH, Lundin J, Blomqvist C: Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest 2001;61:431-441.
36. Kramer G, Steiner GE, Madersbacher S, Stulnig T, Lang T, Marberger M: Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate. J Urol 1997;158:1446-1451.
37. Theyer G, Durer A, Theyer U, Haberl I, Ulsperger E, Baumgartner G, Hamilton G: Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy. Prostate 1999;41:71-77.
38. Kao CH, Gu CJ, Wang SJ: Tissue polypeptide specific antigen in hepatitis B carriers. Anticancer Res 1994;14:2817-2818.
39. Gonzalez-Quintela A, Mella C, Perez LF, Abdulkader I, Caparrini AM, Lojo S: Increased serum tissue polypeptide specific antigen (TPS) in alcoholics: a possible marker of alcoholic hepatitis. Alcohol Clin Exp Res 2000;24:1222-1226.
40. Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Takahara J: Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur Respir J 1999;14:574-578.
41. Fujita J, Dobashi N, Tokuda M, Bandoh S, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ueda Y, Takahara J: Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/ dermatomyositis. J Rheumatol 1999;26:2377-2382.
42. Stigbrand T: The versatility of cytokeratins as tumor markers. Tumour Biol 2001;22:1-3.
43. Björklund B, Björklund V: Specificity and basis of the tissue polypeptide antigen. Cancer Detect Prev 1983;6:41-50.
44. Hembrough TA, Kralovich KR, Li L, Gonias SL: Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J 1996;317:763-769.
45. Godfroid E, Geuskens M, Dupressoir T, Parent I, Szpirer C: Cytokeratins are exposed on the outer surface of established human mammary carcinoma cells. J Cell Sci 1991;99:595-607.
46. Hembrough TA, Li L, Gonias SL: Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem 1996;271:25684-25691.
47. Bodenmüller H, Ofenloch-Hahnle B, Lane EB, Dessauer A, Bottger V, Donie F: Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int J Biol Markers 1994;9:75-81.
48. Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, Yamaji Y, Ohtsuki Y, Dobashi N, Ishida T, Takahara J: The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA 21-1) in human lung cancer cell lines. Int J Cancer 2001;91:468-473.
49. Sheard MA, Vojtesek B, Simickova M, Valik D: Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 2002;85:670-677.
50. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S: Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-1756.
51. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S: Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci USA 2005;102:192-197.
52. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH: Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol 1995;6:3-16.
53. Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S: Measurement of an apoptosis product in the sera of breast cancer patients. Eur J Cancer 2003;39:769-774.
54. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S: Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 2006;94:1592-1598.
55. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T, Manavoglu O: Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 2006;24:669-676.
56. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, Manns MP, Schulze-Osthoff K: Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004;40:1078-1087.
57. Seidel N, Volkmann X, Langer F, Flemming P, Manns MP, Schulze-Osthoff K, Bantel H: The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 2005;42:113-120.
58. Volkmann X, Cornberg M, Wedemeyer H, Lehner F, Manns MP, Schulze-Osthoff K, Bantel H: Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 2006;43:1311-1316.
59. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE: In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33.
60. Roth GA, Krenn C, Brunner M, Moser B, Ploder M, Spittler A, Pelinka L, Sautner T, Wolner E, Boltz-Nitulescu G, Ankersmit HJ: Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients. Shock 2004;22:218-220.
61. Klingström J, Hardestam J, Stoltz M, Zuber B, Lundkvist A, Linder S, Ahlm C: Loss of cell membrane integrity in puumala hantavirus-infected patients correlates with levels of epithelial cell apoptosis and perforin. J Virol 2006;80:8279-8282.
62. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000;97:14608-14613.
63. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'Hara SM, Russell T, Terstappen LW: Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004;62:46-53.
64. Kroemer G, Dallaporta B, Resche-Rigon M: The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998;60:619-642.
65. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
66. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
67. Hägg Olofsson M, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter T, Sonnenberg M, Aulitzky W, Schwarz S, Andersson E, Shoshan MC, Mandic Havelka A, Toi M, Linder S: Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 2007;13:3198-3206.
68. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M: The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007;56:399-404.
69. Sugamura K, Makino M, Kaibara N: Apoptosis as a prognostic factor in colorectal carcinoma. Surg Today 1998;28:145-150.
70. Yamasaki F, Tokunaga O, Sugimori H: Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol 1997;66:439-448.
71. Heatley MK: A high apoptotic index occurs in subtypes of endometrial adenocarcinoma associated with a poor prognosis. Pathology 1997;29:272-275.
72. Kim YH, Lee JH, Chun H, Nam SJ, Lee WY, Song SY, Kwon OJ, Hyun JG, Sung IK, Son HJ, Rhee PL, Kim JJ, Paik SW, Rhee JC, Choi KW: Apoptosis and its correlation with proliferative activity in rectal cancer. J Surg Oncol 2002;79:236-242.
73. Hawkins NJ, Lees J, Ward RL: Detection of apoptosis in colorectal carcinoma by light microscopy and in situ end labelling. Anal Quant Cytol Histol 1997;19:227-232.
74. Koshida Y, Saegusa M, Okayasu I: Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 1997;75:367-373.
75. Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufmann M, Volm M: Spontaneous apoptosis in ovarian cancer: an unfavorable prognostic factor. Int J Oncol 1998;12:351-354.
76. Lipponen P: Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer 1999;6:13-16.
77. Hirvikoski P, Kumpulainen E, Virtaniemi J, Pirinen R, Salmi L, Halonen P, Johansson R, Kosma VM: Enhanced apoptosis correlates with poor survival in patients with laryngeal cancer but not with cell proliferation, bcl-2 or p53 expression. Eur J Cancer 1999;35:231-237.